Want to see FTH full AI Analyst Report?
Faeth Therapeutics (FTH) Stock Forecast & Price Target
FTH Analyst Ratings
Strong Buy
11Buy0Hold0Sell
Based on 11 analysts giving stock ratings to Faeth Therapeutics in the past 3 months
FTH Stock 12 Month Forecast
Average Price Target
$57.60▲(199.53% Upside)Based on 11 Wall Street analysts offering 12 month price targets for Faeth Therapeutics in the last 3 months. The average price target is $57.60 with a high forecast of $70.00 and a low forecast of $40.00. The average price target represents a 199.53% change from the last price of $19.23.
Past 12 Months12 Month ForecastDec2025Sep2026
High$70.00
Average$57.60
Low$40.00
Highest Price TargetHighest$70.00Average Price Target$57.60Lowest Price TargetLowest$40.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Patrick Trucchio | H.C. Wainwright | $60 | buy | 212.01%Upside | Reiterated | 10/27/26 | ||
| Bradley Canino | Guggenheim | $70 | buy | 264.01%Upside | Reiterated | 10/27/26 | ||
| Jeet Mukherjee | BTIG | $55 | buy | 186.01%Upside | Reiterated | 10/26/26 | ||
| Oliver McCammon | LifeSci Capital | $40 | buy | 108.01%Upside | Initiated | 10/15/26 | ||
| Sharon Zackfia | William Blair | $66 | buy | 243.21%Upside | Initiated | 10/15/26 | ||
| Geoff Meacham | Citi | $55 | buy | 186.01%Upside | Reiterated | 10/15/26 | ||
| Dev Prasad | Lucid Capital | $59 | buy | 206.81%Upside | Initiated | 09/14/26 | ||
| Tara Bancroft | TD Cowen | ― | buy | ― | Initiated | 09/09/26 | ||
| Gil Blum | Needham | $56 | buy | 191.21%Upside | Initiated | 08/21/26 | ||
| Jay Olson | Oppenheimer | $60 | buy | 212.01%Upside | Reiterated | 08/05/26 | ||
| Boris Peaker | JonesTrading | $55 | buy | 186.01%Upside | Initiated | 08/04/26 | ||
| Sean McCutcheon | Raymond James | $56 | buy | 191.21%Upside | Initiated | 07/31/26 | ||
| Silvan Turkcan | Citizens JMP | $51 | buy | 165.21%Upside | Initiated | 07/20/26 | ||
| Jack Allen | Robert W. Baird | $57 | buy | 196.41%Upside | Initiated | 06/26/26 | ||
| Li Watsek | Cantor Fitzgerald | ― | buy | ― | Reiterated | 06/03/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Patrick Trucchio | 10/27/26 | $60 | buy | 212.01%Upside | Reiterated | H.C. Wainwright | ||
| Bradley Canino | 10/27/26 | $70 | buy | 264.01%Upside | Reiterated | Guggenheim | ||
| Jeet Mukherjee | 10/26/26 | $55 | buy | 186.01%Upside | Reiterated | BTIG | ||
| Oliver McCammon | 10/15/26 | $40 | buy | 108.01%Upside | Initiated | LifeSci Capital | ||
| Sharon Zackfia | 10/15/26 | $66 | buy | 243.21%Upside | Initiated | William Blair | ||
| Geoff Meacham | 10/15/26 | $55 | buy | 186.01%Upside | Reiterated | Citi | ||
| Dev Prasad | 09/14/26 | $59 | buy | 206.81%Upside | Initiated | Lucid Capital | ||
| Tara Bancroft | 09/09/26 | ― | buy | ― | Initiated | TD Cowen | ||
| Gil Blum | 08/21/26 | $56 | buy | 191.21%Upside | Initiated | Needham | ||
| Jay Olson | 08/05/26 | $60 | buy | 212.01%Upside | Reiterated | Oppenheimer | ||
| Boris Peaker | 08/04/26 | $55 | buy | 186.01%Upside | Initiated | JonesTrading | ||
| Sean McCutcheon | 07/31/26 | $56 | buy | 191.21%Upside | Initiated | Raymond James | ||
| Silvan Turkcan | 07/20/26 | $51 | buy | 165.21%Upside | Initiated | Citizens JMP | ||
| Jack Allen | 06/26/26 | $57 | buy | 196.41%Upside | Initiated | Robert W. Baird | ||
| Li Watsek | 06/03/26 | ― | buy | ― | Reiterated | Cantor Fitzgerald |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Faeth Therapeutics
3 Months
Success Rate2/2 ratings generated profit
100%
Average Return
+103.05%
Copying Li Watsek's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +103.05% per trade.
1 Year
Success Rate1/2 ratings generated profit
50%
Average Return
-5.75%
Copying Li Watsek's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -5.75% per trade.
2 Years
Success Rate1/2 ratings generated profit
50%
Average Return
-5.75%
Copying Li Watsek's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -5.75% per trade.
FTH Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 7 | 13 | 17 | 15 | 16 |
| Buy | 2 | 2 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 9 | 15 | 18 | 17 | 18 |
In the current month, FTH has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. FTH average Analyst price target in the past 3 months is 57.60.
FTH Financial Forecast
High$-0.58
Consensus$-0.78
Low$-1.86
FTH Earnings Forecast
Next quarter’s earnings estimate for FTH is -$0.78 with a range of -$1.86 to -$0.58. The previous quarter’s EPS was -$2.84. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$0.00
Consensus$0.00
Low$0.00
FTH Sales Forecast
Next quarter’s sales forecast for FTH is $0 with a range of $0 to $0. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
FTH Stock Forecast FAQ
What is FTH’s average 12-month price target, according to analysts?
Based on analyst ratings, Faeth Therapeutics’s 12-month average price target is $57.60.
What is FTH’s upside potential, based on the analysts’ average price target?
Faeth Therapeutics has 199.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is FTH a Buy, Sell or Hold?
Faeth Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is Faeth Therapeutics’s price target?
The average price target for Faeth Therapeutics is $57.60. This is based on 11 12-month price targets, issued in the past 3 months. The highest analyst price target is $70.00, the lowest forecast is $40.00. The average price target represents a 199.53% increase from the current price of $19.23.
What do analysts say about Faeth Therapeutics?
Faeth Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Street analysts.
How can I buy shares of FTH?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
